Introduction
Human 17b-hydroxysteroid dehydrogenase type 10 is a multifunctional protein encoded by the HSD17B10 (formerly HADH2) gene (OMIM300256) [1] . Human HSD10 cDNA was cloned from brain (NM_004493), and the resulting protein, a homotetramer [2, 3] (Fig. 1 ), was first characterized as a short chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD) [2, 4, 5] . Active sites of this enzyme can accommodate different substrates; 17b-HSD10 is involved in the oxidation of isoleucine, branched-chain fatty acids, and xenobiotics as well as the metabolism of sex hormones and neuroactive steroids (Table 1 ) [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] .
17b-HSD10 is the sole 17b-hydroxysteroid dehydrogenase, out of 14 different types, that is localized in the mitochondria [16, 17] . Ever since the role of this mitochondrial enzyme in the metabolism of steroid hormones and neuroactive steroids was recognized [4, 5, 15] , it has been designated as 17b-hydroxysteroid dehydrogenase type 10 (17b-HSD10) [18, 19] . This enzyme also can form complexes with other proteins to generate mtRNase P activity [20] . When 17b-HSD10 binds to estrogen receptor alpha or amyloid b-peptides, various 17b-HSD10 functions are inhibited [21, 22] . The molecular weight of 17b-HSD10/SCHAD that is composed of four identical subunits is 108 kDa; each subunit consists of 261 amino acid residues [2] . Although the endoplasmic reticulum-associated amyloid-b peptide binding protein (ERAB) was reported to be associated with the ER and to consist of 262 residues with a molecular weight of 27 kDa [23, 24] , ERAB is actually identical to 17b-HSD10/SCHAD [2] that is localized in mitochondria but not ER [4, 5, 15, 18, 19] . In experimental animals, rat 17b-HSD10 and mouse 17b-HSD10 encoded by the rat Hsd17b10 gene and the mouse Hsd17b10 gene, respectively, are also localized in the mitochondria [25, 26] . Nevertheless, generalized alcohol dehydrogenase activity and triple intracellular localization was attributed to ERAB by publishing artifacts. On the basis of such misconceptions, ERAB [6, 23] was renamed Ab-binding alcohol dehydrogenase (ABAD) [6, 27] . Later reports claimed that ABAD concentrates in mitochondria [28] , yet made no reference to published characterizations of 17b-HSD10/SCHAD [2, 4, 5, 15, 18, 19] .
17b-HSD10 deficiency -a progressive infantile neurodegeneration

Mutation hotspot
The HSD17B10 gene maps to a chromosomal region closely associated with X-linked mental disorders [29] . In addition to its enzymatic activities, the capability of 17b-HSD10 to bind to various peptides also is believed to play an important role in human health and disease [30] . Missense mutations in the HSD17B10 gene result in a progressive infantile neurodegeneration [31] , namely 17b-HSD10 deficiency (OMIM#300438). About 50% of such cases are caused by a c.388C>T transition due to a 5-methylcytosine hotspot, which was identified at the +2259 nucleotide from the initiation codon ATG of the HSD17B10 gene [32] .
Mimics a mitochondrial disease
Individuals with 17b-HSD10 deficiency may have microcephaly but no dysmorphism or organomegaly. One of the predominant clinical features of this disease is psychomotor regression whose onset often occurs at 6-36 months after birth [8, [30] [31] [32] [33] [34] [35] [36] [37] [38] . Mimicking a mitochondrial disease [37] , the cells of 17b-HSD10 deficient patients exhibit mitochondrial morphology that is severely altered such that the majority of mitochondria appear to be rounded with depleted cristae [38] . 
Clinical hallmark -a blockade of isoleucine degradation
Because 17b-HSD10 (formerly SCHAD [1, 7, 8, 10 ] is a key enzyme in the isoleucine oxidation pathway (Fig. 2 ), all individuals with 17b-HSD10 deficiency have a blockade of isoleucine degradation [8, 34, 39] . Some patients who have a mild mental disability have normal levels of isoleucine metabolites in the blood because they carry a silent mutation, c.574C>A, in the HSD17B10 gene [40] . They suffer from X-linked mental disabilities, choreoathetosis and abnormal behavior (MRXS10) [41] (OMIM#300220) -but not 17b-HSD10 deficiency. In some individuals with 17b-HSD10 deficiency, one biochemical finding of mitochondrial dysfunction is an increase in lactate levels [42] . No signs of abnormal ketone body metabolism are exhibited, and the oxidation of D-3-hydroxybutyrate catalyzed by 17b-HSD10, if any [27] , is insignificant (Table 1) . Although elevated levels of isoleucine metabolites in blood and their excretion in urine are a clinical hallmark of 17b-HSD10 deficiency, the accumulation of tiglylglycine and 2-methyl-3-hydroxybutyrate is perhaps only a pathophysiological background of this disease; an imbalance in neurosteroid metabolism could be a major cause of the observed neurological handicap [8] .
A low-protein, high-energy dietary regimen with carnitine supplementation reduces the accumulation of isoleucine metabolites in blood and urine (Fig. 3) , but it cannot ameliorate the patients' psychomotor regression [31] [32] [33] .
Metabolism of allopregnanolone
Allopregnanolone (ALLOP) is a potent, positive allosteric modulator of GABA A receptors, and has a significant impact on the GABA A receptor plasticity [43] [44] [45] . ALLOP can be de novo synthesized in the central nervous system by the reduction of progesterone to 5a-dihydroprogesterone (5a-DHP) under the catalysis of 5a-reductase. 5a-DHP has no effect on GABA A receptors, but it can be further reduced to ALLOP by the oxidation of NADPH under the catalysis of 3a-hydroxysteroid dehydrogenase type 3 (3a-HSD3) [46] . Since the ratio of NADPH/NADP + is much greater than 10 in the cytosol [47] and since 3a-hydroxysteroid dehydrogenase type 3 (AKR1C2) itself prefers to form an EÁNADPH binary complex, 3a-HSD3 acts predominantly as a 17-ketosteroid reductase (AKR1C2) to generate ALLOP. As a result, any serious discussion of the metabolism of ALLOP has to include a reliable mechanism that could effectively inactivate ALLOP. It was reported [12, 48] that mitochondrial 17b-HSD10, but not 3a-HSD3 (AKR1C2), should be responsible for the catalysis of the oxidative inactivation of ALLOP. Since NAD + is the coenzyme of 17b-HSD10 that is localized in mitochondria where the ratio of NADH/NAD + is about 0.1, ALLOP is converted back to 5a-DHP in mitochondria. Two distinct enzymes, i.e., 3a-HSD3 (AKR1C2) and 17b-HSD10, in two different compartments have a part to play in the metabolism of ALLOP (Fig. 4) . When neuronal progenitors migrate from the ventricular zone to the cortical plate region they become predominantly GABAergic [49] . A normal level of wild type 17b-HSD10 is, therefore, essential for brain development and cognitive function. The imbalance of neuroactive steroid metabolism, especially ALLOP metabolism, in brains of individuals with 17b-HSD10 deficiency remains to be studied. Such investigations would lay a foundation for the effective treatment of this kind of developmental intellectual disabilities.
Ab undetectable in patient's cerebrospinal fluid
Whether the amyloid-b peptide is involved in the infantile neurodegeneration of 17b-HSD10 deficiency is of great interest. It was recently reported [50] that Ab peptide is undetectable in the cerebrospinal fluid (CSF) of an individual with 17b-HSD10 deficiency. If this observation is confirmed in other affected individuals, the implication would be that a missense mutation in the HSD17B10 gene could alter the metabolism or trafficking of the amyloid precursor protein (APP) [51] . Because APP is a known risk factor for AD, studies on 17b-HSD10 deficiency may lead to new avenues for the treatment of AD.
Misconceptions in 17b-HSD10 research
3.1. Is Ab-binding alcohol dehydrogenase really an alcohol dehydrogenase?
The myth of generalized alcohol dehydrogenase activity
Literature references to Ab-binding alcohol dehydrogenase (ABAD) as a recharacterization of ERAB [6, 27, 28] -itself a misnomer for 17b-HSD10 -do not account for the establishment of 17b-HSD10/SCHAD as a mitochondrial hydroxysteroid dehydrogenase [2] [3] [4] [5] 11, 15, 18, 19] . The ABAD designation relied on a reported generalized alcohol dehydrogenase activity that purportedly catalyzed the oxidation of a variety of aliphatic alcohols in which the alkyl groups range from n-decanol (C10) to ethanol (C2). According to the published Experimental Procedure section of the key reference that attempted to establish ERAB as ABAD, the "[a]lcohol dehydrogenase assays employed ERAB/HADHII (20 mg/ ml), a range of alcohol substrates and concentrations (methanol, ethanol, n-propanol, isopropanol, n-butanol, (AE)-2-octanol, (+)-2- a The absorbance change (DA340) is within the instrumental error range of the UV spectrophotometer when 7% alcohol solution was used as substrate in the alcohol dehydrogenase assay. This alcohol concentration is about 100 times higher than the DWI (driving while intoxicated) limit.
octanol, (À)-2-octanol, and n-decanol; Sigma), and NAD + (7.5 mM) in 22 mM sodium pyrophosphate, 0.3 mM sodium phosphate (pH 8.8). The reaction was run for 2 h at 25 C, and the absorbance at 340 nm was monitored every 5 min as described above." [6] . These conditions raise very serious concerns about the reliability of the results as described below.
As is well known, n-decanol and 2-octanol are immiscible with water. For example, the saturating concentration of 2-octanol is no more than 7 mM [52] ; immiscibility has no exceptions among enantiomers: (AE)-2-octanol, (+)-2-octanol, or (À)-2-octanol. 160 mM or even 210 mM (À)-2-octanol was reportedly used as substrates for the alcohol dehydrogenase assays [6] (Fig. 5) . Because no solubilization method was ever reported, it is not possible to reproduce the assays that purportedly establish ERAB/ ABAD's generalized alcohol dehydrogenase activity. In addition, the catalytic rates of ABAD/ERAB reported for other substrates, such as 17b-estradiol and acetoacetyl-CoA, appear to have been exaggerated by three orders of magnitude and by five-fold, respectively [5] .
Negligible alcohol dehydrogenase activity of 17b-HSD10
Although ethanol is an alcohol miscible with water, the reported turnover rate (k cat ) catalyzed by ABAD/ERAB was 0.5 per second when a 1.21 M ethanol solution was used as substrate [6] . Therefore, these data establish that it is perfectly proper to designate this mitochondrial enzyme 17b-hydroxysteroid dehydrogenase type 10 [4,18,19] , which is encoded by the human HSD17B10 gene, as designated by the Human Gene Nomenclature Committee (HGNC) [53] . Nonetheless, it was reported [6] that "the combination of Ab binding properties and generalized alcohol dehydrogenase activity, in addition to HADH activity, lead us to propose the new name Ab binding alcohol dehydrogenase or ABAD to better describe the unusual properties of the enzyme previously referred to as ERAB or HADH II". This statement conflicts with the facts about 17b-HSD10. Although 17b-HSD10 is known to have an affinity for other peptides, including Ab [30] , it exhibits only a negligible alcohol dehydrogenase activity ( Table 1 ). The aim of this review is to dispel the mischaracterization of the generalized alcohol dehydrogenase activity of ABAD/ERAB. Only then can the research on this important brain enzyme 17b-HSD10 move forward. Fig. 3 . Changes of isoleucine metabolite levels in 17b-HSD10 deficiency patient's urine due to the low-protein dietary regimen. Urine organic acids were analyzed as trimethylsilyl (TMS)-derivatives by gas chromatography-mass spectrometry. Urine organic acid profiles: (A) normal control; (B) 17b-HSD10 deficiency patient; (C) 17b-HSD10 deficiency patient under low protein dietary regimen. 2MHBA, 2-methyl-3-hydroxybutyrate; EHA, 2-ethylhydracrylic acid; TG, tiglylglycine; IS, internal standard. (Adapted from Fig. 1 of [33] ). Fig. 4 . Roles of brain 17b-HSD10 in the metabolism of allopregnanolone (ALLOP). ALLOP is a positive steroid modulator of GABA A receptors that potentiates GABA to increase the opening of Cl À channels. ALLOP is generated from 5a-dihydroprogesterone (DHP) by cytosolic 3a-HSD3 catalysis, whereas ALLOP is oxidized to 5a-DHP that has no effect 
Invalid competitive inhibition constants (K i ) of Ab
Further confusion concerning 17b-HSD10 was engendered by reports of kinetic studies of ABAD/ERAB. 17b-HSD10 is inhibited by the binding of estrogen receptor alpha [21] or Ab peptides that include residues 12-24 [22] . The inhibition of 17b-HSD10 activities by Ab reportedly follows a one-site model for competitive inhibition [6] , for which a well-known enzyme kinetics book [54] had been cited as the specific reference. However, only a single, fixed substrate concentration was used to study the competitive inhibition of ABAD/ERAB, which is inadequate to establish the competitive inhibition. More surprisingly, competitive inhibition constants (K i ) of Ab were reportedly obtained by fitting data to a one-site model for competitive inhibition (Fig. 5  bottom part A, B, and C) . In fact, no such "one-site model for competitive inhibition" is described in the cited reference [54] . Thus, it seems unlikely that any of the K i values of Ab reported for ABAD/ERAB [6, 55, 56] would be valid. The one-site competitive inhibition model is another misconception that has emerged from ABAD/ERAB studies [6, 27, 28] . The validity of ABAD/ERAB reports in AD research [55] [56] [57] [58] [59] [60] [61] [62] [63] needs to be reexamined.
Does 17b-HSD10 have triple intracellular localization?
ERAB, a misnomer of 17b-HSD10, was reportedly localized in ER, and would migrate to the plasma membrane after cells are incubated with Ab peptides [23] (Fig. 6) . However, the reported migration of 17b-HSD10 from ER to plasma membrane [23, 24] is not reproducible except those shown in Fig. 6 of [6] , because 17b-HSD10 is, indeed, localized in mitochondria but not ER according to honest immunocytochemical studies (Fig. 7) [4, 15] .
Confirmation of erroneous data by distorted subcellular fractionation
The localization of 17b-HSD10 in the mitochondria, ER, and plasma membrane has been confirmed by subcellular fractionation data [6, 27] . The fractionation experimental procedure employed in ABAD/ERAB studies was reportedly described in a particular reference [64] . Unfortunately, there is only half of a sentence relevant to the fractionation experimental procedure, i.e., "[f]ractionation of cell lysates was performed as described (24), . . . .". As a matter of fact, the actually employed procedure [6, 27] has nothing to do with the subcellular fractionation described in the indirectly cited literature [65] , the purpose of which is to isolate nuclei for the purification of a transcription factor [65] . If the conventional method instead of the distorted subcellular fractionation procedure was performed, 17b-HSD10 cannot be detected in the ER fraction (Fig. 8) . Data from the honest immunocytochemical studies were perfectly corroborated by data obtained from the conventional subcellular fractionation experiments, because 17b-HSD10 possesses a non-cleavable mitochondrial targeting signal at its N-terminus (residues 1-11) [15, 18, 19] .
Cytochrome C used as the mitochondrial marker
As indicated by Nobel laureate Christian de Duve, cytochrome C is readily released from damaged mitochondria. The use of cytochrome C rather than cytochrome C oxidase as a marker for mitochondria in ABAD/ERAB studies [6, 27] resulted in additional artifacts [18] that further promoted ABAD/ERAB's erroneous and astonishing story.
Misconceptions that emerged from ABAD/ERAB studies have severely impacted 17b-HSD10 research. It is hoped that in the future, erroneous triple intracellular localization of 17b-HSD10 in public databases (Supplementary Materials S1) based upon reports that are not supported by any reliable data, will be corrected, and that the underlying reports [6, 23, 24, 27, 28] will be withdrawn.
Significance of 17b-HSD10 for Alzheimer's disease (AD)
Elevated levels of 17b-HSD10 in AD brains
The 17b-HSD10 sequence and the coding nucleotide sequence of the HSD17B10 gene are highly conserved among animals and appear to be indispensable for life [66, 67] . 17b-HSD10 is present in brain regions at different levels, and is most abundant in the hippocampus [48] . 17b-HSD10 concentrations in the CSF may reflect its quantity in the brain. It was reported [68] that 17b-HSD10 concentration in the CSF declines with age, yet there is 5.7-fold more 17b-HSD10 in AD patients' CSF than in corresponding age-matched controls. Furthermore, abundant 17b-HSD10 is found in the brains of AD patients [48] as well as of an AD mouse model [26] (Fig. 9) . It has been reported [11] that overexpression of 17b-HSD10 results in mitochondrial matrix condensation and partial loss of cristae structure.
Oligomeric Ab bound to 17b-HSD10
The D loop of 17b-HSD10 has a short b hairpin structure and extends the subunit interface in the homotetramer by contacting the helix aE2 of an adjacent monomer (Fig. 1) . A unique insertion I region of the D loop can bind Ab [3] . The dissociation constant of the Ab-17b-HSD10 complex is about 88 nM, and oligomeric rather than monomeric Ab would inhibit 17b-HSD10 [56] . It was claimed that the D-loop is disordered and submerged to a large solvent channel as shown in Fig. 2D of ref. 28. The D-loop could perhaps binds with several Ab peptides. Nevertheless, no electron density for Ab in the 17b-HSD10-Ab crystal was observed [28] (Supplementary Materials S2). The precise oligomeric state of Ab that binds to 17b-HSD10 has not been established. Since the inhibition of 17b-HSD10 requires micromolar concentration of Ab [22] , aggregation of Ab is necessary to distort the NAD + binding site [69] .
4.3. Limited role of 17b-HSD10 in the production of energy 17b-HSD10 was originally identified as short chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD) [2] . It is clear that L-3-hydroxyacyl-CoA dehydrogenase (HAD) but not 17b-HSD10/ SCHAD plays an essential role in the mitochondrial fatty acid b-oxidation [7, [70] [71] [72] . Unfortunately, for the rationalization of reports in literature claiming 17b-HSD10 to be a genuine alcohol dehydrogenase and therefore designated as amyloid beta-peptidebinding alcohol dehydrogenase (ABAD) [6, 27, 28, 56, 57] , it was asserted [56] that the catalytic mechanism of L-3-hydroxyacyl-CoA dehydrogenase [73] is the reaction mechanism of ABAD catalyzing the oxidation of alcohols to ketones (Scheme 1. Reduction and oxidation of alcohols and ketones by ABAD of [56] ). In fact, L-3-hydroxyacyl-CoA dehydrogenase (HAD) and 17b-HSD10/SCHAD are two distinct enzymes belonging to two different dehydrogenase families, respectively [7, 70, 71, 74] .
The conflation of one with the other serves to confuse the function of 17b-HSD10 as an alcohol dehydrogenase that oxidizes alcohols and ketone bodies to supply energy. Although this proposition sounds plausible because of the observation that glucose metabolism is reduced in AD brains [75] , 17b-HSD10 plays only a limited role in the production of energy, indeed. It is well known that the oxidation of ketone bodies is catalyzed by human D-3-hydroxybutyrate dehydrogenase [76, 77] rather than by 17b-HSD10, for which the catalytic efficiency for D-3-hydroxybutyrate is negligible (Table 1) . Thus, the proposition that an amyloid betapeptide-binding alcohol dehydrogenase is a component of the cellular response to nutritional stress [27] sends a misleading message.
Impairment of mitochondria due to abnormality of 17b-HSD10
It has been reported [6] that cells expressing both bAPP(V717G) and 17b-HSD10 (ABAD/ERAB) generate toxic aldehydes, e.g., 4-hydroxy-2-nonenal (4-HNE) whereas those expressing both bAPP (V717G) and mutant 17b-HSD10(Y168G/K172G) do not. However, it was later reported [78] that 17b-HSD10 can actually detoxify 4-HNE.
17b-HSD10 is a putative intracellular mediator for Ab neurotoxicity because it is one of dozen proteins that can bind to Ab [30, 62, 79] . However, no coherent mechanistic explanation has yet been postulated for this toxicity [80] . Mitochondrial dysfunction and oxidative stress seem to play a key role in the pathogenesis of AD [81] . Oxidative damage occurs early in the brains of AD patients, and also precedes Ab deposition in an AD mouse model [82] . The binding of Ab to 17b-HSD10 in mitochondria might increase lipid peroxidation and reactive oxygen species (ROS) release. ROS, in turn, would activate band g-secretase and facilitate the amyloidogenic cleavage of the amyloid-b precursor molecule. Ab would further induce free radicals and so affect glycolysis, the tricarboxylic acid (TCA) cycle, and the respiratory chain -especially complex IV activity - leading to reduced glucose metabolism and reduced ATP production (Fig. 10) [79] . Opening of the mitochondrial permeability transition pore (mPTP), the disturbance of Ca ++ homeostasis, the release of cytochrome C, and the activation of caspases would eventually lead to DNA fragmentation and cell death. It was reported [83] that ALLOP would directly inhibit mPTP and thus protect neurons. Damage to mitochondria would also cause impairment of mitochondrial transport, imbalance of mitochondrial fission/ fusion, and abnormal mitochondria dynamics [79, 84] . Mitochondrial function, positioning, and shape all impact brain function and cognition [85, 86] . Because synaptic mitochondria are more vulnerable than perinuclear mitochondria, synaptic deficiency occurs in the early stage of AD.
Possible target for treatment of AD
Mitochondrial 17b-HSD10 levels are significantly increased in the brains of individuals with AD and in an AD mouse model [26, 48] . It has also been reported that 17b-HSD10 levels are increased in the brains of individuals with multiple sclerosis [68] and are decreased in the brains of a Parkinson's disease (PD) mouse model [87] . 17b-HSD10 is involved in the progression of 17b-HSD10 deficiency and AD because 17b-HSD10 plays an important role in the metabolism of neuroactive steroids, e.g., 17b-estradiol and allopregnanolone [1, 4, 5, 7, 8, [10] [11] [12] [13] 15, 18, 19, 30, 48, 88] (Fig. 4) .
The question of whether changes of 17b-HSD10 levels [48, 68, 71, 87, 89] in the above-mentioned neurological disorders and ulcerative colitis are due to alterations of HSD17B10 gene expression remains to be answered. To date, studies on the regulatory mechanism of HSD17B10 gene expression have been limited [90, 91] . The mechanism by which elevated levels of 17b-HSD10 would cause the increase of 'downstream' proteins such as peroxiredoxin-2 [92] and endophilin-1 [93] remains unknown. However, what is known is that the inhibitory effect of Ab on mtRNase P is not generated via the interaction of Ab and 17b-HSD10 [94] .
It was reported [28] that a decoy peptide synthesized according to the D loop sequence of 17b-HSD10 (residue 92-120) would reduce the binding of Ab to 17b-HSD10 and thus improve mitochondrial function in an AD mouse model. However, parenteral administration of a synthetic peptide to human may cause immunological responses. Even if such a decoy peptide could pass the blood-brain barrier and eventually enter into mitochondria, it is not known how it might avoid degradation by mitochondrial peptidases such as prolyl endopeptidase [95] and insulin-degrading enzyme [96] . Thus, this decoy peptide does not appear to be a feasible strategy for treatment of AD patients.
The etiology of late-onset AD remains elusive. An imbalance of neuroactive steroid metabolism may have an important part to play in neurodegenerative disorders [4, 8, 19] . The neuroprotective and neurotrophic effects of 17b-estradiol and allopregnanolone are well documented [43, [97] [98] [99] [100] [101] . 17b-estradiol and allopregnanolone levels are reduced in the brains of individuals with AD [19, 44, 98, 102] . A proper dosing and treatment regimen will be a key to have success in a clinical trial of the neuroactive steroid supplementation. The inhibition of 17b-HSD10 would increase these neuroprotective steroid levels in the brain [4, 88] , given that 17b-HSD10 is present in different brain regions and catalyzes the oxidation of 17b-estradiol and allopregnanolone [4, 5, [10] [11] [12] [13] 48] ( Table 1 and Fig. 4) . A suicide inhibitor of 17b-HSD10 has already been tested [88] (Fig. 1) . Recently, a reversible, specific steroidal inhibitor of 17b-HSD10 was also developed [103] , which may be more suitable to the pharmaceutical industry. Approaches to restore steroid homeostasis in AD brains, including the adjustment of 17b-HSD10 activity, are therapeutic modalities that warrant further exploration.
Concluding remarks
17b-HSD10 is the sole 17b-hydroxysteroid dehydrogenase in mitochondria. Earlier studies indicating that 17b-HSD10 is also localized in the plasma membrane, cytoplasm and endoplasmic reticulum have been proved to be incorrect. Furthermore, studies have shown that this enzyme does not possess generalized alcohol dehydrogenase activity. Missense mutations in the HSD17B10 gene result in 17b-HSD10 deficiency, an infantile neurodegenerative disorder. Since allopregnanolone, a positive steroid modulator of GABA A receptors synthesized in cytosol by 3a-HSD3 catalysis, is inactivated by the catalysis of mitochondrial 17b-HSD10, the imbalance of neuroactive steroid metabolism is probably a major cause. Elevated levels of 17b-HSD10 are present in the brains of individuals with AD and of an AD mouse model, but the implications of these findings have been neglected while investigators focused on the erroneous findings of the ABAD/ ERAB studies. The rectification of these misconceptions about 17b-HSD10 should promote more progress in this field. Imbalanced neuroactive steroid metabolism appears to be associated with mitochondrial dysfunction in brain. The restoration of neuroactive steroid homeostasis should be a future research direction, which may create a new approach to the treatment of AD and other neurodegenerative disorders.
